Top 5 Target	Count

PDL1(Programmed death-ligand 1)	1
CTLA4(Cytotoxic T-Lymphocyte-Associated Antigen 4)	1
CD4(T-cell surface antigen CD4)	1
CCR4(C-C chemokine receptor type 4)	1

Drugs associated with Crown Bioscience, Inc.

10B-10

Target

CTLA4

Mechanism

CTLA4 inhibitors

Active Org.

Zhejiang Crownmab Biotech Co. Ltd. [+2]

Originator Org.

Crown Bioscience, Inc.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

WO2024163530

Patent Mining

Target

CCR4

Mechanism-

Active Org.

Crown Bioscience, Inc.

Originator Org.

Crown Bioscience, Inc.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date-

WO2022216887

Patent Mining

Target

CD4

Mechanism-

Active Org.

Crown Bioscience, Inc.

Originator Org.

Crown Bioscience, Inc.

Active Indication

Hemic and Lymphatic Diseases [+2]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Crown Bioscience, Inc.

NCT00477282

/ CompletedPhase 3

A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer

The objective of this study is to assess the safety and efficacy of karenitecin versus topotecan in patients with platinum/taxane-resistant advanced epithelial ovarian cancer. Additionally, this study will assess the ability of karenitecin to extend the time to disease progression, extend the overall survival time, and reduce the incidence and severity of treatment related hematological toxicities in patients with advanced epithelial ovarian cancer.

Start Date01 Aug 2007

Sponsor / Collaborator

BioNumerik Pharmaceuticals, Inc.

[+1]

NCT00097903

/ CompletedPhase 1

Phase 1 Trial of Oral Karenitecin® in Patients With Solid Tumors"

The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.

Start Date01 May 2004

Sponsor / Collaborator

BioNumerik Pharmaceuticals, Inc.

[+1]

NCT00062491

/ CompletedPhase 2

Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma

The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.

Start Date01 May 2002

Sponsor / Collaborator

BioNumerik Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Crown Bioscience, Inc.

0 Patents (Medical) associated with Crown Bioscience, Inc.

Literatures (Medical) associated with Crown Bioscience, Inc.

01 Jan 2025·ANTICANCER RESEARCH

Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers

Article

Author: An, Xiaoyu ; Yang, Huajun ; Kunz, Ryan ; Zang, Mingfa ; Li, B O ; Erickson, Brian ; Littlefield, Bruce A ; Zheng, Jia

BACKGROUND/AIM:

Preclinical studies were undertaken to investigate whether eribulin's known cytotoxic antimitotic effects are characterized by immunogenic cell death (ICD) as assessed by three established ICD biomarkers: extracellular released ATP, released HMGB1 and cell surface calreticulin.

MATERIALS AND METHODS:

Using BT-549, Hs578T and MCF-7 breast cancer cell lines, antiproliferative IC₅₀'s of eribulin, five other microtubule targeting agents (MTAs; ER-076349, vinblastine, vinorelbine, paclitaxel, docetaxel) and three DNA damaging agents (DDAs; doxorubicin, cisplatin, oxaliplatin) were determined.

RESULTS:

Treatment of cells with 10×IC₅₀ concentrations of all drugs in serum-free media resulted in time-dependent induction of cytotoxicity over DMSO controls. Measurement of ATP and HMGB1 released into conditioned media and appearance of cell surface calreticulin support eribulin's ability to induce ICD. Compared to the other agents tested, eribulin's potency as an ICD inducer was mid-range and shared with vinblastine, paclitaxel, doxorubicin and oxaliplatin. Interestingly, MTAs as a group appeared to be more potent inducers of ATP release compared to DDAs, whereas DDAs appeared to be more potent inducers of cell surface calreticulin compared to MTAs. Overall, drug effects on ATP release and cell surface calreticulin showed early peaking followed by rapid decline, while effects on HMGB1 release were generally slower and more prolonged.

CONCLUSION:

Our results support the concept that eribulin's cytotoxic effects are associated with ICD. These findings provide impetus for investigating how eribulin-induced ICD may contribute to the larger spectrum of phenotypic and immunological effects by which eribulin exerts antitumor therapeutic benefits.

01 Aug 2024·Cancer research communications

Mathematical Modeling of Tumor Growth in Preclinical Mouse Models with Applications in Biomarker Discovery and Drug Mechanism Studies

Article

Author: Zhou, Huajun ; Mao, Binchen ; Guo, Sheng

Abstract:

Oncology drug efficacy is evaluated in mouse models by continuously monitoring tumor volumes, which can be mathematically described by growth kinetic models. Although past studies have investigated various growth models, their reliance on small datasets raises concerns about whether their findings are truly representative of tumor growth in diverse mouse models under different vehicle or drug treatments. In this study, we systematically evaluated six parametric models (exponential, exponential quadratic, monomolecular, logistic, Gompertz, and von Bertalanffy) and the semiparametric generalized additive model (GAM) on fitting tumor volume data from more than 30,000 mice in 930 experiments conducted in patient-derived xenografts, cell line–derived xenografts, and syngeneic models. We found that the exponential quadratic model is the best parametric model and can adequately model 87% studies, higher than other models including von Bertalanffy (82%) and Gompertz (80%) models; the latter is often considered the standard growth model. At the mouse group level, 7.5% of growth data could not be fit by any parametric model and were fitted by GAM. We show that endpoint gain integrated in time, a GAM-derived efficacy metric, is equivalent to exponential growth rate, a metric we previously proposed and conveniently calculated by simple algebra. Using five studies on paclitaxel, anti-PD1 antibody, cetuximab, irinotecan, and sorafenib, we showed that exponential and exponential quadratic models achieve similar performance in uncovering drug mechanism and biomarkers. We also compared exponential growth rate–based association analysis and exponential modeling approach in biomarker discovery and found that they complement each other. Modeling methods herein are implemented in an open-source R package freely available at https://github.com/hjzhou988/TuGroMix.

Significance::

We present a general strategy for mathematically modeling tumor growth in mouse models using data from 30,000 mice and show that modeling and nonmodeling approaches are complementary in biomarker discovery and drug mechanism studies.

12 Jul 2024·Oncotarget

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death

Article

Author: An, Xiaoyu ; Bosch, Marion T J van den ; Boer, Harm C den ; Schaapveld, Roel Q J ; Wang, Jingjing ; Wang, Fang ; Shao, Yingying ; Yahyanejad, Sanaz ; Zang, Mingfa ; Vos, Rogier M ; Bourré, Ludovic ; Duurland, Chantal L ; Xie, Xiaolei ; Janicot, Michel ; Gunst, Thijs de ; Telford, Bryony J ; Cai, Jie ; Pinxteren, Laurens A H van

microRNAs (miRNAs) are small, non-coding RNAs that regulate expression of multiple genes. MiR-193a-3p functions as a tumor suppressor in many cancer types, but its effect on inducing specific anti-tumor immune responses is unclear. Therefore, we examined the effect of our lipid nanoparticle (LNP) formulated, chemically modified, synthetic miR-193a-3p mimic (INT-1B3) on anti-tumor immunity. INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival. INT-1B3-treated animals were fully protected against challenge with autologous tumor cells even in absence of treatment indicating long-term immunization. Protection against autologous tumor cell challenge was hampered upon T cell depletion and adoptive T cell transfer abrogated tumor growth. Transfection of tumor cells with our miR-193a-3p mimic (1B3) resulted in tumor cell death and apoptosis accompanied by increased expression of DAMPs. Co-culture of 1B3-transfected tumor cells and immature DC led to DC maturation and these mature DC were able to stimulate production of type 1 cytokines by CD4+ and CD8+ T cells. CD4-CD8- T cells also produced type 1 cytokines, even in response to 1B3-transfected tumor cells directly. Live cell imaging demonstrated PBMC-mediated cytotoxicity against 1B3-transfected tumor cells. These data demonstrate for the first time that miR-193a-3p induces long-term immunity against tumor development via modulation of the tumor microenvironment and induction of immunogenic cell death.

News (Medical) associated with Crown Bioscience, Inc.

11 Dec 2024

·www.businesswire.com

Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership

SAN DIEGO--( BUSINESS WIRE )--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, has been honored with the 2024 Fierce CRO Award for Excellence in Client Service and Partnership. This prestigious award recognizes Crown Bioscience's outstanding collaboration, communication, and commitment to delivering excellence for its life sciences clients. The Fierce CRO Awards, hosted annually by Fierce Biotech, celebrate the achievements of leading CROs that demonstrate innovation and leadership in accelerating drug development. Winners in this category are selected based on their commitment to building strong partnerships and providing an exceptional client experience. "Winning this award is a true testament to our team’s dedication to going above and beyond for our clients," said Dr. Jonny McMichael, Vice President of Client Experience and Enablement at Crown Bioscience. "We aim to accelerate the journey of new therapies by collaborating closely with our partners across the drug development continuum." Crown Bioscience stood out for its innovative preclinical research capabilities, transparent communication practices, and unwavering focus on delivering quality and value to clients. Specific achievements highlighted include the company's Customer Satisfaction Program , which generates unfiltered feedback scores to demonstrate its commitment to service and customer excellence. "This recognition motivates us to continue raising the bar for the CRO industry," Dr. McMichael added. "We are thankful to our entire team for making Crown Bioscience a trusted, client-focused partner in the mission to bring new treatments to patients faster and more efficiently." The full Fierce CRO Awards report profiling all winners is available here . Crown Bioscience's award-winning capabilities can be explored at www.crownbio.com . About Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com

22 Aug 2024

·www.pharmaceutical-technology.com

CTI announces partnership for oncology drug development

The combined expertise is expected to ensure a more effective path to clinic. Credit: Salov Evgeniy/Shutterstock. CTI Clinical Trial & Consulting Services (CTI) and Crown Bioscience have announced a strategic partnership aimed at bolstering consulting services for oncology drug development. The collaboration brings together CTI’s clinical and regulatory expertise with Crown Bioscience’s preclinical and translational models, aiming to streamline the transition of oncology compounds from discovery to early-phase global studies. It is set to benefit customers by providing expert guidance that enhances the efficiency of oncology drug development. CTI Global Laboratory Services business development vice-president Ryan Gifford stated: “Crown Bioscience’s leadership in early-phase oncology research and suite of preclinical services complement CTI’s broad spectrum of capabilities. “Together, we can offer enhanced support to our oncology clients and deepen our commitment to advancing cancer research.” See Also: FDA approves updated mRNA vaccines for Covid-19 Verve Therapeutics gets grant for gene editing compositions to lower ldl cholesterol levels The combined expertise is expected to ensure an effective path to clinic, support long-term success in drug development and accelerate the delivery of new oncology treatments to patients. Through the alliance, customers will have access to a range of consulting services designed to foster an integrated approach to drug development. These services include strategic preclinical development planning, study data analysis and interpretation, de novo assay development and regulatory guidance. Crown Bioscience commercial senior vice-president Alex Slater stated: “Crown Bioscience has an established reputation for exceeding the typical services offered by a regular CRO [contract research organisation]. “This initiative unites deep-seated expertise spanning all phases of drug development, marking a pivotal step towards delivering a true translational offer to our clients.” In November 2023, Crown Bioscience launched its service offering , OrganoidXplore to meet the demands of research initiatives by offering a diverse selection of models that cover a wide spectrum of genetic backgrounds and mutations.

VaccinemRNAClinical Study

21 Aug 2024

·www.businesswire.com

Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development

SAN DIEGO--( BUSINESS WIRE )-- Crown Bioscience , a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting services. This collaboration unites decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space. Customers will benefit from combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase clinical trials more rapidly and effectively. This alliance aims to determine the optimal and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of superior oncology therapeutics to patients. From today, customers can access consulting services to ensure an integrated drug development approach, including: Strategic preclinical development planning Study data analysis, interpretation and advice Regulatory guidance De novo assay development Grant review Alex Slater, Senior Vice President of Commercial, commented: ‘’Crown Bioscience has an established reputation for exceeding the typical services offered by a regular CRO. This initiative unites deep-seated expertise spanning all phases of drug development, marking a pivotal step towards delivering a true translational offer to our clients.’’ Ryan Gifford, Vice President of Global Laboratory Services, Business Development, shares: ‘’We are delighted to collaborate with Crown Bioscience and view this as a valuable synergy. Crown Bioscience’s leadership in early-phase oncology research and suite of preclinical services complement CTI’s broad spectrum of capabilities. Together, we can offer enhanced support to our oncology clients and deepen our commitment to advancing cancer research.’’ About Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com About CTI Clinical Trial & Consulting Services CTI Clinical Trial and Consulting Services is a global, privately held, research service organization, delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides clinical and disease area expertise with nuanced regulator support. CTI also offers a fully integrated multi-specialty clinical research site and complete global laboratory services. Now in its third decade, CTI is one of the 20 largest contract research organizations in the world, with associates in more than 60 countries across six continents. CTI is headquartered in the Greater Cincinnati area, with operations across North America, Europe, Latin America, MEA, and Asia-Pacific. For more information, visit www.ctifacts.com .

Clinical Study

100 Deals associated with Crown Bioscience, Inc.

100 Translational Medicine associated with Crown Bioscience, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 16 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

10B-10 ( CTLA4 )	Neoplasms More	Preclinical
WO2022216887 ( CD4 )Patent Mining	Hemic and Lymphatic Diseases More	Discovery
WO2023143478 ( PDL1 )Patent Mining	Neoplasms More	Discovery
WO2024163530 ( CCR4 )Patent Mining	Neoplasms More	Discovery
MEB-4906 ( μ opioid receptor )	Pain More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis